14.3.3η (eta) Test Ordering Update
As of November 6th, Quest Diagnostics will no longer offer the 14.3.3eta Protein – Test Code 91455. Augurex is dedicated to supporting your patients with diagnostic testing solutions in rheumatoid arthritis (RA) and other autoimmune conditions with joint involvement.
To avoid any disruptions in care for your patients, you can continue to order 14.3.3eta from Labcorp without delay as a standalone test and as part of various panels for diagnosis1-2, prognosis3-4, and monitoring5-6 of RA. For reference, all impacted Quest 14.3.3eta test codes are listed below alongside their equivalent Labcorp test codes.
| Impacted Quest Test Code | Equivalent Test Codes at Labcorp |
| 91455 (14.3.3eta Protein) | 504550 (14.3.3eta Protein) |
| 91472 (RA Diagnostic Panel 2 - RF, anti-CCP, 14.3.3eta) | 504509 (RheumAssure – RF, anti-CCP, 14.3.3eta) |
| 94954 (ANA, IFA, Cascade & RA Panel 2 with Reflexes | 382965 + 504509 (ANA, IFA, Reflex & RheumAssure) |
In addition to the equivalent offerings above, Labcorp offers novel testing solutions that support the entire continuum of care for rheumatic diseases. Additional panels at Labcorp that contain 14.3.3eta, and uniquely aid in the diagnosis and management of patients with RA are referenced below.
| Test Code | Description |
|---|---|
| 520304 - RAdx6 Profile | The RAdx6 combines four novel markers (14.3.3eta, Anti-Sa, Anti-CEP-1, and Anti-CarP) with two traditional markers (Anti-CCP and RF-IgM) to enhance diagnosis in early or established RA and help predict disease severity. |
| 520305 - SeroNeg RAdx4 Profile | SeroNeg RAdx4 is a diagnostic and prognostic panel including 14.3.3eta, Anti-Sa, Anti-CEP-1 and Anti-CarP for RA designed to complement traditional RF and Anti-CCP testing. |
| 520298 - RA Profile reflex to SeroNeg RAdx4 | Profile includes 14.3.3eta, Anti-Sa, Anti-CEP-1, and Anti-CarP, enhancing RA diagnosis, predicting severity, identifying RA in Anti-CCP/IgM-RF-negative patients, and aiding early RA diagnosis. |
Please provide your contact information below to access essential resources and stay informed about the latest advancements in diagnostic testing for RA and related conditions.
Available to order at:
Labcorp is your trusted source for RA testing services.
Click here for a full list of solutions.
The 14.3.3eta blood test is covered by CMS and Health Insurance Providers
References
- Maksymowych WP, Boire G, van Schaardenburg D, et al. 14.3.3η Autoantibodies: Diagnostic Use in Early Rheumatoid Arthritis. J Rheumatol 2015;42(9):1587-1594. PubMed 26178283
- Maksymowych WP, Naides SJ, Bykerk V, et al. Serum 14.3.3η is a novel marker that complements current serological measurements to enhance detection of patients with rheumatoid arthritis. J Rheumatol 2014;41(11):2104-2113. PubMed 25128504
- Maysymowych WP, van der Heijde D, Allaart CF, et al. 14.3.3η is a novel mediator associated with the pathogenesis of rheumatoid arthritis and joint damage. Arthritis Res Ther. 2014 Apr;16(2):R99. PubMed 24751211
- Carrier N, Marotta A, de-Brum-Fernandes AJ, et al. Serum levels of 14.3.3η protein supplement C-reactive protein and rheumatoid arthritis-associated antibodies to predict clinical and radiographic outcomes in a prospective cohort of patients with recent-onset inflammatory polyarthritis. Arthritis Res Ther 2016 Feb 1;18:37. PubMed 26832367
- Shovman O, Gilburd B, Watad A, Amital H, Langevitz P, Bragazzi NL, Adawi M, Perez D, Lidar M, Katz I, Blank M, Biln NK, Marotta A, Shoenfeld Y. Decrease in 14.3.3η protein levels is correlated with improvement in disease activity in patients with rheumatoid arthritis treated with Tofacitinib. Pharmacol Res. 2019 Mar;141:623-626. PubMed 30414892.
- Hirata S, Marotta A, Gui Y, Hanami K, Tanaka Y. Serum 14.3.3η level is associated with severity and clinical outcomes of rheumatoid arthritis, and its pretreatment level is predictive of DAS28 remission with tocilizumab. Arthritis Res Ther. 2015 Oct 9;17:280. PubMed 26449724